ReviewThe Journal of biological chemistry2026
TNF-alpha: Roles in pathogenesis and therapeutics in cancer.
Review in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Inflammation and carcinogenesis: molecular targets and small-molecule intervention strategies.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Glutathione-Responsive Acyl-Modifications for Targeted RNA Decaging and Prolonged Protein Synthesis.Angewandte Chemie (International ed. in English) · 2026Article
- Alantolactone Activates the Extracellular Signal-Regulated Kinase Signaling Pathway to Promote Tumor Necrosis Factor Receptor 1 Ectodomain Shedding.Molecules (Basel, Switzerland) · 2026Article
- NExON-Bayes: a Bayesian approach to network estimation informed by ordinal covariates.Bioinformatics (Oxford, England) · 2026Article
- Myeloid landscape of BRAF-mutant papillary thyroid cancer and thyroiditis.Endocrine-related cancer · 2026Article
- Review
- Association of Polymorphisms of Inflammatory-Relevant Genes with Cancer Risk.Current issues in molecular biology · 2026Article
- Article
- Obesity-associated inflammation and cancer: molecular mechanisms, evidence gaps, and therapeutic opportunities.Frontiers in immunology · 2026Review
- Revisiting B-cell targeted therapies in rheumatoid arthritis: from paradoxical biology to deep immune reset.Frontiers in immunology · 2026Review
- Cytokine and chemokine networks in colorectal cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Tumor necrosis factor alpha (TNF-α) is a pleiotropic cytokine that can both facilitate tumor progression and directly mediate tumor cell killing. This dual role creates a conundrum in which TNF can be either beneficial or detrimental for a tumor, depending on the context. Herein, we describe the history of the cytokine, the cases in which TNF-α has been considered as a cancer immunotherapy, and the toxicities that can manifest from its use. We also add context to its activity, particularly in T cells (via the engagement of TNF receptors) as well as the epigenetic and immunoregulatory pathways that are elicited. Furthermore, we highlight the fundamental differences in the transcriptional and translational regulation of this cytokine, which plays a significant role in the context of malignancy and potential success of immunotherapies. This review aims to provide insight and background on molecular switches, cellular context, and TNF receptor dynamics that determine the role of TNF-α as both tumor suppressor and promoter in different models, which is essential for deriving maximal benefit from TNF therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.